Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 154-160

  Moody, Terry W ^a   Switzer, Christopher ^a   Santana Flores, Wilmarie ^a   Ridnour, Lisa A ^a   Berna, Marc ^b   Thill, Michelle ^b   Jensen, Robert T ^b   Sparatore, Anna ^c   Del Soldato, Piero ^d   Yeh, Grace C ^e   Roberts, David D ^a   Giaccone, Giuseppe ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d Sulfidris   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

E cadherin; Lung cancer; PGE2; S diclofenac; S valproate

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CAY 10404; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DITHIOLETHIONE; NITRIC OXIDE; PROSTAGLANDIN E2; SULFUR; SULINDAC; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VALPROIC ACID; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANETHOLE TRITHIONE; ANIMALS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOXAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRAZOLES; SULFONES; VALPROIC ACID;

EID: 77950519857     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.012     Document Type: Article

References (43)

1. Sekido Y., Fong K.M., Minna J.D. Molecular biology of lung cancer. Cancer: principles and practice of oncology 2005, 745-752. Lippincott Williams and Wilkins, Philadelphia. V.T. DeVita, S. Helman, S.A. Rosenberg (Eds.).
2. Lynch T., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350(May 20 (21)):2129-2139. [Epub 2004, April 29. PubMed PMID:15118073].
3. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGF receptor mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(June 4 (5676)):1497-1500. [Epub 2004, April 29. PubMed PMID:15118125].
4. Hida T., Leyton J., Makheja A.N., Ben-Av P., Hla T., Martinez A., et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res 1998, 18(March-April (2A)):775-782. [PubMed PMID:9615719].
5. Heasley L.E., Thaler S., Nicks M., Price B., Skorecki K., Nemenoff R.A. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997, 272(June 6 (23)):14501-14504. [PubMed PMID:9169405].
6. Krysan K., Lee J.M., Dohadwala M., Gardner B.K., Reckamp K.L., Garon E., et al. Inflammation, epithelial to mesenchymal transition and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 2008, 3(February 3 (2)):107-110. [PubMed PMID:18303428].
7. Sun S.Y., Schroeder C.P., Yue P., Lothan D., Hong W.K., Lotan R. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther 2005, 4(April 4 (4)):407-413. [Epub 2005 April 21. PubMed PMID:15846100].
8. Komaki R., Liao Z., Milas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 2004, 31(February (1)):47-53. [PubMed PMID:14981580].
9. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response of preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 2003, 21(July 15 (14)):2645-2650. [PubMed PMID:12869939].
10. Gadgeel S.M., Ali S., Philip P.A., Ahmed F., Wozniak A., Sarkar F.H. Response of dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in non-small cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 2007, 110(December 15 (12)):2775-2784. [PubMed PMID:17948911].
11. Reckamp K.L., Gardner B.K., Figlin R.A., Elashoff D., Krysan K., Dohadwala M., et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 2008, 3(February 3 (2)):117-124. [PubMed PMID:18393430].
12. Fidler M.J., Argiris A., Patel Y.D., Johnson D.H., Sandler A., Villaflor V.M., et al. The potential predictive values of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008, 14(April 1 (7)):2088-2094. [PubMed PMID:18381949].
13. Kashfi K., Borgo S., Williams J.L., Chen J., Gao J., Glekas A., et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005, 312(March 31 (3)):978-988. [Epub 2004, November 4. PubMed PMID:15528453].
14. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappa B and NO synthase inhibition: implications for chemoprevention. Cancer Res 2003, 63(November 15 (22)):7613-7618. [PubMed PMID:14697260].
15. Gao J., Liu X., Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 2005, 102(November 22 (47)):17207-17212. [PubMed PMID:16282376].
16. Isenberg J.S., Jia Y., Field L., Ridnour L.A., Sparatore A., Del Soldato P., et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 2007, 151(May (1)):63-72. [Epub 2007 April 5. PubMed PMID:17351657].
17. Smith C.J., Zhang Y., Koboldt C.M., Mohammad J., Zweifel B.S., Shaffer A. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998, 95(October 27 (22)):13313-13318. [PubMed PMID:9789085].
18. Habeeb A.G., Rao P.N., Knaus E.E. Design and syntheses of diarylisoxazoles: novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-anti-inflammatory activity. Drug Dev Res 2000, 51:273-286. [PubMed PMID:11520213].
19. Dohadwala M., Yang S.C., Luo J., Sharma S., Batra R.K., Huang M., et al. COX-2 dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in NSCLC. Cancer Res 2006, 66(May 15 (10)):5338-5345. [PubMed PMID:16707460].
20. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008, 25(6):629-642. [Epub 2008 May 7. PubMed PMID:18461285].
21. Barr S., Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008, 25(6):685-693. [Epub 2008 January 31. PubMed PMID:18236164].
22. Peinado H., Olmeda D., Cano A., Snail Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7(June 7 (6)):415-428. [Epub 2007 May 7. PubMed PMID:17508028].
23. Das A.K., Sato M., Story M.D., Peyton M., Graves R., Redpath S., et al. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006, 66(October 1 (19)):9601-9608. [PubMed PMID:17018617].
24. Miyanaga A., Gemma A., Ando M., Kosaihira S., Noro R., Minegishi Y., et al. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncol Rep 2008, 19(February (2)):377-383. [PubMed PMID:18202784].
25. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell 2002, 9(February (2)):213-224. [PubMed PMID:11864595].
26. Ohira T., Gemmill R.M., Ferguson K., Kusy S., Roche J., Brambilla E., et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 2003, 100(September 2 (18)):10429-10434. [Epub 2003 August 22. PubMed PMID:12937339].
27. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66(January 15 (2)):944-950. [PubMed PMID:16424029].
28. Perrino E., Cappelletti G., Tazzari V., Giavini E., Del Soldato P., Sparatore A. New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett 2008, 18(May 15 (6)):1893-1897. [Epub 2008 February 8. PubMed PMID:18294844].
29. Salon C., Lantuejoul S., Eymin B., Gazzeri S., Brambilla C., Brambilla E. The E-cadherin-β-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol 2005, 1(October (5)):649-660. [PubMed PMID:16556042].
30. Coffey R.J., Hawkey C.J., Damstrup L., Graves-Deal R., Daniel V.C., Dempsey P.J., et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997, 94(January 21 (2)):657-662. [PubMed PMID:9012840].
31. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinoma. Gastroenterology 1994, 107(October (4)):1183-1188. [PubMed PMID:7926468].
32. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinoma. Cancer Res 1998, 58(September 1 (17)):3761-3764. [PubMed PMID:9731479].
33. Marnett L.J., DuBois R.N. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002, 42:55-80. [PubMed PMID:11807164].
34. Jaffe B.M., Parker C.V., Philpott G.W. Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic culture tissue. Surg Forum 1971, 22:90-92. [PubMed PMID:5121477].
35. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6(September (3)):285-295. [PubMed PMID:5121477].
36. Li L., Rossoni G., Sparatore A., Lee L.C., Del Soldato P., Moore P.K. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007, 42(March 1 (50)):706-719. [Epub 2006 December 16. PubMed PMID:17291994].
37. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60(September 1 (17)):4705-4708. [PubMed PMID:10987272].
38. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87(November 29 (5)):803-809. [PubMed PMID:8945508].
39. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93(May 29 (5)):705-716. [PubMed PMID:9630216].
40. Casibang M., Purdom S., Jakowlew S., Neckers L., Zia F., Ben-Av P., et al. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001, 31(February-March (2-3)):203-212. [PubMed PMID:11165399].
41. Casibang M., Moody T.W. AH6809 antagonizes non-small cell lung cancer prostaglandin receptors. Lung Cancer 2002, 36(April (1)):33-42. [PubMed PMID:11891031].
42. Keith R.L., Geraci M.W., Nan-Sinkam S.P., Breyer R.M., Hudish T.M., Meyer A.M., et al. Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res 2006, 26(July-August (4B)):2857-2861. [PubMed PMID:16886605].
43. 2 activated MAPK/Erk pathway in non-small cell lung cancer cells in an EGF receptor-independent manner. Cancer Res 2005, 65(July 15 (14)):6275-6281. [PubMed PMID:16024629].